BRIEF published on 10/11/2024 at 07:35, 1 year 8 months ago Poxel Releases 2023 Universal Registration Document Corporate Governance Annual Financial Report CSR Report Poxel 2023 Registration Document
PRESS RELEASE published on 10/11/2024 at 07:30, 1 year 8 months ago Annual financial and audit reports / Terms of availability of the annual financial report Poxel announces availability of the 2023 Universal Registration Document including financial and governance reports, now filed with the AMF AMF Biopharmaceutical Company Financial Report Universal Registration Document Poxel
BRIEF published on 10/03/2024 at 18:35, 1 year 8 months ago Poxel announces its financial and strategic results for 2023 Financial Results Biopharmaceutical TWYMEEG® Poxel OrbiMed
BRIEF published on 09/30/2024 at 07:35, 1 year 8 months ago Poxel Secures $50M Non-Dilutive Financing from OrbiMed Non-dilutive Financing TWYMEEG® Poxel Royalty Monetization OrbiMed
PRESS RELEASE published on 09/30/2024 at 07:30, 1 year 8 months ago Inside Information / Other news releases Poxel monetizes TWYMEEG® royalties in a USD 50 million deal with OrbiMed. Proceeds to reduce debt and support rare disease activities. Webinars scheduled for investor updates Webinars Royalties TWYMEEG® Poxel OrbiMed
BRIEF published on 09/09/2024 at 07:35, 1 year 9 months ago POXEL announces a significant increase in its sales in the second quarter of 2024 Sales Treasury Partnerships TWYMEEG® Poxel
BRIEF published on 08/16/2024 at 08:16, 1 year 10 months ago Poxel: Evolution of the Share Capital and the Number of Voting Rights Share Capital Voting Rights Actions AMF Poxel
BRIEF published on 08/07/2024 at 08:05, 1 year 10 months ago Sumitomo Pharma and Poxel Unveil Study Results of TWYMEEG® for Type 2 Diabetes TWYMEEG® Poxel Sumitomo Pharma Type 2 Diabetes Renal Failure
PRESS RELEASE published on 08/07/2024 at 08:00, 1 year 10 months ago Inside Information / Other news releases Sumitomo Pharma and Poxel announce topline results from post-marketing clinical study on TWYMEEG(R) for Type 2 Diabetes treatment in Japan. Safety, tolerability confirmed in renal impairment patients Japan Poxel Sumitomo Pharma Type 2 Diabetes TWYMEEG
Published on 06/25/2026 at 00:30, 7 hours 29 minutes ago Northern Dynasty Reports Annual General Meeting Results and Welcomes New Directors
Published on 06/24/2026 at 23:05, 8 hours 54 minutes ago Polaris Modifies Quorum Requirement for Upcoming AGM
Published on 06/24/2026 at 22:15, 9 hours 44 minutes ago Organto Foods Announces Annual General Meeting Results
Published on 06/24/2026 at 21:20, 10 hours 39 minutes ago Taranis to Explore New Properties East of Thor Mineral Resource
Published on 06/24/2026 at 20:10, 11 hours 49 minutes ago Fox River Obtains Final Order Approving Plan of Arrangement With Avenir Minerals Limited
Published on 06/25/2026 at 07:25, 34 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Update on APAC matter
Published on 06/25/2026 at 07:20, 39 minutes ago CGTN: How 'China Opportunity 2.0' offers growth potential for global businesses
Published on 06/25/2026 at 07:00, 59 minutes ago 4th Chain Expo "Launchpad" Kicks Off with Over 30 Launch Events to Be Held
Published on 06/25/2026 at 07:00, 59 minutes ago Swiss Prime Site to breathe new life into the Maag halls
Published on 06/25/2026 at 07:00, 59 minutes ago DocMorris announces accelerated implementation of its “AI-First” strategy; positive cost savings of at least CHF 15 million per year
Published on 06/25/2026 at 07:30, 29 minutes ago Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
Published on 06/24/2026 at 17:45, 14 hours 14 minutes ago Air Liquide continues its long-term growth in Kazakhstan with a key investment to support Silleno's world-scale plant
Published on 06/24/2026 at 17:40, 14 hours 19 minutes ago Report on share repurchases from 17 to 23 June 2026
